This clinical trial is focused on studying treatments for people with advanced HIV infection. The study is comparing two different types of medications used to treat HIV. One group of participants will receive a treatment called Symtuza, which is a combination of four substances: emtricitabine, tenofovir alafenamide, darunavir, and cobicistat. The other group will receive a treatment called Biktarvy, which combines emtricitabine, tenofovir alafenamide, and bictegravir. The purpose of the study is to see if the treatment with an integrase inhibitor, like Biktarvy, is as effective or better than a boosted protease inhibitor, like Symtuza, for patients with advanced HIV.
Participants in the study will take their assigned medication in the form of film-coated tablets, which are taken orally. The study will last for a period of 48 weeks, during which time participants will be monitored to see how well the medication works in controlling the virus and improving their immune system. The study will also look at the safety and tolerability of the medications, which means checking for any side effects or reactions to the treatment. Throughout the study, the health and progress of the participants will be closely observed to gather information on how the treatments affect their HIV infection.
The study aims to provide valuable insights into the effectiveness of these two treatment options for people with advanced HIV. By comparing the two medications, researchers hope to determine which treatment might be more beneficial for patients who are starting therapy later in the course of their disease. This information could help guide future treatment decisions for people living with HIV.
Belgium 
France 
Germany 
Ireland 
Italy 
Spain 
